—
—
In Stock
Wegovy (semaglutide) is a prescription GLP-1 receptor agonist used as part of a comprehensive treatment plan that includes a reduced-calorie diet and increased physical activity. According to current FDA labeling, Wegovy injection is indicated for long-term weight reduction and maintenance in eligible adults and certain adolescents with obesity, as well as certain adults with overweight and a weight-related condition. It is also indicated for reducing the risk of certain major cardiovascular events in eligible adults with established cardiovascular disease. Treatment should be used under the direction of a qualified healthcare professional. Patients should review the prescribing information, including contraindications, warnings, potential adverse reactions, and dosing instructions, before treatment.
